BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29697005)

  • 1. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.
    Ludmir EB; Milgrom SA; Pinnix CC; Gunther JR; Westin J; Oki Y; Fayad LE; Medeiros LJ; Dabaja BS; Nastoupil LJ
    Leuk Lymphoma; 2018 Dec; 59(12):2896-2903. PubMed ID: 29697005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
    Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
    Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
    Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
    Ryan GF; Roos DR; Seymour JF
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):337-41. PubMed ID: 16507213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients.
    Tokola S; Kuitunen H; Turpeenniemi-Hujanen T; Kuittinen O
    Cancer Med; 2020 Mar; 9(6):1966-1977. PubMed ID: 31967739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin lymphoma of the breast.
    Ganjoo K; Advani R; Mariappan MR; McMillan A; Horning S
    Cancer; 2007 Jul; 110(1):25-30. PubMed ID: 17541937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.
    Ryan G; Martinelli G; Kuper-Hommel M; Tsang R; Pruneri G; Yuen K; Roos D; Lennard A; Devizzi L; Crabb S; Hossfeld D; Pratt G; Dell'Olio M; Choo SP; Bociek RG; Radford J; Lade S; Gianni AM; Zucca E; Cavalli F; Seymour JF;
    Ann Oncol; 2008 Feb; 19(2):233-41. PubMed ID: 17932394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
    Hu S; Song Y; Sun X; Su L; Zhang W; Jia J; Bai O; Yang S; Liang R; Li X; Zhang H; Gao Y; Zhang W; Xiao X; Bao H; Wang N; Ren H; Cen X; Yang S; Zhao Y; Wang Y; Wang Y; Liu A; Wang J; Shi Y; Yuan M; Li Y; He X
    Cancer Sci; 2018 Dec; 109(12):3943-3952. PubMed ID: 30302857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary breast lymphoma--a report of 27 cases with literature review].
    Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY
    Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
    J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
    Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
    Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
    Fukuhara S; Watanabe T; Munakata W; Mori M; Maruyama D; Kim SW; Kobayashi Y; Taniguchi H; Maeshima AM; Tanosaki R; Matsuno Y; Tobinai K
    Eur J Haematol; 2011 Nov; 87(5):434-40. PubMed ID: 21740461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
    Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
    Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.